These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 36758550)
21. Safety and Efficacy of [ Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824 [No Abstract] [Full Text] [Related]
22. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796 [TBL] [Abstract][Full Text] [Related]
23. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172 [TBL] [Abstract][Full Text] [Related]
30. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
31. Prediction of Response to Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546 [TBL] [Abstract][Full Text] [Related]
32. Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile. Demirkol MO; Esen B; Seymen H; Şen M; Uçar B; Kurtuldu S; Mandel NM; Bavbek S; Falay O; Tilki D; Esen T Clin Nucl Med; 2023 Dec; 48(12):e564-e569. PubMed ID: 37844332 [TBL] [Abstract][Full Text] [Related]
33. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081 [TBL] [Abstract][Full Text] [Related]
36. Comparison of novel PSMA-targeting [ Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2794-2805. PubMed ID: 38658392 [TBL] [Abstract][Full Text] [Related]
37. Change in total lesion PSMA (TLP) during [ Burgard C; Hein C; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S; Rosar F Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):885-895. PubMed ID: 37889298 [TBL] [Abstract][Full Text] [Related]
38. RECIP 1.0 Predicts Progression-Free Survival After [ Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143 [TBL] [Abstract][Full Text] [Related]
39. Radioligand Therapy With Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089 [No Abstract] [Full Text] [Related]